Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Boston Scientific
BSX
$74.2B
| $147M | 0.19% |
5,305,605
-421,100
| -7% | -$11.2M |
|
102
Equity Lifestyle Properties
ELS
$12.4B
| $145M | 0.19% |
3,369,000
+598,600
| +22% | +$24.9M |
|
103
National Grid
NGG
$80.7B
| $143M | 0.18% |
2,581,503
-144,440
| -5% | -$8.82M |
|
104
Danaher
DHR
$146B
| $143M | 0.18% |
1,914,667
+268,577
| +16% | +$20.1M |
|
105
Take-Two Interactive
TTWO
$46.8B
| $143M | 0.18% |
1,951,950
+1,781,500
| +1,045% | +$122M |
|
106
Autodesk
ADSK
$53.1B
| $140M | 0.18% |
+1,391,968
| New | +$138M |
|
107
Simon Property Group
SPG
$71.2B
| $140M | 0.18% |
866,005
-208,900
| -19% | -$34M |
|
108
Devon Energy
DVN
$49.9B
| $140M | 0.18% |
4,376,500
+2,370,500
| +118% | +$86.7M |
|
109
Gen Digital
GEN
$17.4B
| $137M | 0.18% |
4,857,838
+3,897,200
| +406% | +$118M |
|
110
Progressive
PGR
$123B
| $136M | 0.17% |
3,085,200
+400,700
| +15% | +$16.6M |
|
|
B
111
Barrick Mining
B
$67.2B
| $136M | 0.17% |
8,539,099
+451,300
| +6% | +$7.72M |
|
112
Sysco
SYY
$40.3B
| $136M | 0.17% |
2,693,200
-1,161,000
| -30% | -$62M |
|
|
FLG
113
Flagstar Bank National Association
FLG
$5.89B
| $135M | 0.17% |
3,429,800
+214,241
| +7% | +$8.52M |
|
114
American International
AIG
$40.4B
| $134M | 0.17% |
+2,149,060
| New | +$134M |
|
115
NetApp
NTAP
$38.9B
| $134M | 0.17% |
3,339,574
+2,960,542
| +781% | +$118M |
|
116
Old Republic International
ORI
$10.2B
| $133M | 0.17% |
6,825,385
+815,600
| +14% | +$16.3M |
|
117
Thermo Fisher Scientific
TMO
$224B
| $133M | 0.17% |
760,144
-612,900
| -45% | -$103M |
|
118
Kinross Gold
KGC
$32.3B
| $131M | 0.17% |
32,172,372
-811,000
| -2% | -$3.23M |
|
|
AZPN
119
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $130M | 0.17% |
2,360,500
+408,200
| +21% | +$22.6M |
|
120
Campbell Soup
CPB
$6.78B
| $130M | 0.17% |
2,494,700
+2,130,700
| +585% | +$121M |
|
|
ABMD
121
DELISTED
Abiomed Inc
ABMD
| $128M | 0.16% |
893,223
+224,523
| +34% | +$30.2M |
|
122
Chemours
CC
$2.23B
| $127M | 0.16% |
3,342,200
+310,800
| +10% | +$12.3M |
|
123
Dollar Tree
DLTR
$24.6B
| $126M | 0.16% |
1,801,303
+967,500
| +116% | +$74.7M |
|
|
NTRI
124
DELISTED
NutriSystem, Inc.
NTRI
| $126M | 0.16% |
2,414,100
-73,800
| -3% | -$3.82M |
|
125
Usana Health Sciences
USNA
$254M
| $125M | 0.16% |
1,948,266
+186,600
| +11% | +$11.5M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.